BTLA expression is induced during activation of T cells, and BTLA remains expressed on Th1 cells but not Th2 cells. Like PD1 and CTLA4, BTLA interacts with a B7 homolog, B7H4. However, unlike PD-1 and CTLA-4, BTLA displays T-Cell inhibition via interaction with tumor necrosis family receptors (TNF-R), not just the B7 family of cell surface receptors. BTLA is a ligand for tumour necrosis factor (receptor) superfamily, member 14 (TNFRSF14), also known as herpes virus entry mediator (HVEM). BTLA-HVEM complexes negatively regulate T-cell immune responses.
BTLA activation inhibits the function of human CD8+ cancer-specific T cells.
↑Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM (July 2003). "BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1". Nature Immunology. 4 (7): 670–9. doi:10.1038/ni944. PMID12796776.
Pao LI, Bedzyk WD, Persin C, Cambier JC (February 1997). "Molecular targets of CD45 in B cell antigen receptor signal transduction". Journal of Immunology. 158 (3): 1116–24. PMID9013950.
Pao LI, Cambier JC (March 1997). "Syk, but not Lyn, recruitment to B cell antigen receptor and activation following stimulation of CD45- B cells". Journal of Immunology. 158 (6): 2663–9. PMID9058799.
Vilen BJ, Famiglietti SJ, Carbone AM, Kay BK, Cambier JC (July 1997). "B cell antigen receptor desensitization: disruption of receptor coupling to tyrosine kinase activation". Journal of Immunology. 159 (1): 231–43. PMID9200459.
Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM (December 2003). "Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2". Biochemical and Biophysical Research Communications. 312 (4): 1236–43. doi:10.1016/j.bbrc.2003.11.070. PMID14652006.
Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, Scheu S, Pfeffer K, Ware CF, Murphy TL, Murphy KM (January 2005). "B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator". Nature Immunology. 6 (1): 90–8. doi:10.1038/ni1144. PMID15568026.
Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG (November 2005). "Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex". The Journal of Biological Chemistry. 280 (47): 39553–61. doi:10.1074/jbc.M507629200. PMID16169851.
Otsuki N, Kamimura Y, Hashiguchi M, Azuma M (June 2006). "Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells". Biochemical and Biophysical Research Communications. 344 (4): 1121–7. doi:10.1016/j.bbrc.2006.03.242. PMID16643847.
Wang XF, Chen YJ, Wang Q, Ge Y, Dai Q, Yang KF, Zhou YH, Hu YM, Mao YX, Zhang XG (February 2007). "Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells". Tissue Antigens. 69 (2): 145–53. doi:10.1111/j.1399-0039.2006.00710.x. PMID17257317.